Last reviewed · How we verify
Cetuximab Radioimmunotherapy
Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload.
Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload. Used for Colorectal cancer, Head and neck cancer.
At a glance
| Generic name | Cetuximab Radioimmunotherapy |
|---|---|
| Also known as | Erbitux |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Drug class | Monoclonal antibody |
| Target | EGFR |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This treatment works by using cetuximab, a monoclonal antibody that binds to EGFR on cancer cells, and then attaching a radioactive payload to the antibody. The radioactive payload then destroys the cancer cells. This approach is designed to minimize damage to healthy cells while targeting and eliminating cancer cells.
Approved indications
- Colorectal cancer
- Head and neck cancer
Common side effects
- Fatigue
- Diarrhea
- Skin rash
- Mucositis
- Hypomagnesemia
Key clinical trials
- Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (PHASE2)
- Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades (NA)
- TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors (PHASE2)
- Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (PHASE1, PHASE2)
- Treatment Selection According to Skin Reaction to Cetuximab (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: